AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low and epinephrine
Description: A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
Study NCT03399435 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin combined with bupivacaine low
Description: A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
Study NCT03894917 — intervention group
Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: Assessments will be done for participants that are 65 years or older.
Study NCT02401672 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
Study NCT02984540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
Study NCT02984540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet
Description: Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to \<40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
Study NCT01645709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT01645709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02157558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: All subjects will receive 180 mg fexofenadine
Study NCT02157558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
Study NCT01463605 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg,once per week,for 5 to 6 weeks
Study NCT01916018 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and radiologic exams and blood samples
Study NCT01398605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Different dose of exercise training
Study NCT03646513 — intervention group
Intervention type: DEVICE
Intervention: SMF Short Modular Femoral Hip System
Description: Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
Study NCT00112073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: IV, Q13w
Study NCT00112073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV Q13w
Study NCT02905526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive instant messages
Description: Contraceptive Instant messages
Study NCT02905526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone app
Description: Mobile phone app
Study NCT02905526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone app
Description: Mobile phone app
Study NCT04192097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professionalism curriculum
Description: One year training program including ten two-hours sessions about~* Knowing yourself~* Interaction with patients and their families~* Teamwork and organization with colleagues
Study NCT01269892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: lactose-free milk
Description: a milk without lactose
Study NCT01269892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: conventional milk
Description: a milk with lactose
Study NCT03236103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Recommendations
Description: The clinical recommendations will regard the following:~1. Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~2. Optimizing volume status (avoidance of volume overload or depletion)~3. Optimizing electrolytes and acid-base status~4. Optimizing hemodynamics (Mean arterial BP>65mmHg)~5. Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice.
Study NCT03259035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: 6 cycles of q2weekly FOLFOX, or
Study NCT03259035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capox
Description: 4 cycles of q3weekly CAPOX
Study NCT03407638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROUD Intervention
Description: The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
Study NCT02545894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Description: The tasks are:~* visually tracking a picture as it moves across the computer screen~* pressing a button every time a picture is seen on the screen~* pressing a button every time a specific picture is seen on the screen~* Pressing a button every time a specific sound is heard~* Matching objects to a picture~* Matching gestures to objects~* Matching two connected objects~* Sorting objects by categories~* Matching sounds to objects~* Complete the category and odd on out with objects~* Choosing target objects by pointing~* Choosing objects to complete the category by pointing
Study NCT02012374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Language Action Therapy
Study NCT03544034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HomeTeam Toolkit
Description: A multi-component intervention (8S's)~1. Safety at home through partnership.~2. Safety risk assessment at the admission~3. Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~4. Safety tools. Cognitive tools to support patient/family after discharge~5. Safety education. Enhanced Patient/ family medication safety education~6. Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~7. Safety through learning routines across the care continuum~8. Safety assessment after discharge
Study NCT01851057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR
Description: Problem-solving and education intervention (8 total sessions)
Study NCT01851057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only
Description: Education around epilepsy (8 total sessions)
Study NCT04842695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture group
Description: compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
Study NCT04842695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture group
Description: compare the effectiveness of electroacupuncture on point B7 plus pelvic floor exercises versus pelvic floor exercises alone in women with urinary incontinence (UI) .
Study NCT00723177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV411
Description: Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
Study NCT00723177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PCB)
Description: Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
Study NCT04109989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HominisTM Surgical System
Description: Trans-vaginal gynecological procedures
Study NCT00931177 — intervention group
Intervention type: OTHER
Intervention: weight
Description: weight and dehydration scores
Study NCT00931177 — intervention group
Intervention type: OTHER
Intervention: weight and dehydration score
Description: weight and dehydration score
Study NCT00245557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks.
Study NCT03359096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic HGNS
Description: Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
Study NCT03359096 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Subtherapeutic 'Sham' HGNS
Description: Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds
Study NCT04130061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Membrane
Description: Epicardial application of human amniotic membrane during cardiac surgery
Study NCT04146441 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: 1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
Study NCT04146441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: FOLFIRINOX Regime according to Norwegian national guidelines
Study NCT04146441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: FOLFIRINOX Regime according to Norwegian national guidelines
Study NCT00938288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KW-3357
Description: 50IU/mL, IV single dose
Study NCT02294461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT02294461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT03322579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilatation Eustachian tuboplasty
Description: Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
Study NCT02907502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Young-child formula with low protein content
Description: Young-child formula with low protein content
Study NCT02308033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Study NCT02308033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel vehicle
Study NCT01084044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ulinastatin, saline solution
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
Study NCT01084044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulinastatin, saline solution
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
Study NCT01084044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin, saline solution
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
Study NCT02332486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qingxuan Decoction
Description: In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
Study NCT01176253 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
Study NCT02907502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Young-child formula with protein content similar to that of cow's milk
Description: Young-child formula with protein content similar to that of cow's milk
Study NCT04630873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.
Study NCT04630873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.
Study NCT04630873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: gait analysis
Description: The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
Study NCT04630873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: gait analysis
Description: The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
Study NCT02065882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT524 (fibrinogen concentrate from human plasma)
Description: single intravenous infusion
Study NCT02525562 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon Total Knee System with X3 insert
Description: Total knee replacement
Study NCT02525562 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Scorpio NRG Total Knee System with X3 insert
Description: Total knee replacement
Study NCT02525562 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PKR System with X3 insert
Description: Partial Knee Resurfacing
Study NCT02525562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Replacement
Description: Total Knee Replacement
Study NCT02525562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial Knee Resurfacing
Description: Partial Knee Resurfacing
Study NCT00300573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexelvucitabine
Description: nucleoside inhibitor of HIV Reverse Transcriptase
Study NCT00300573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexelvucitabine
Description: nucleoside inhibitor of HIV Reverse Transcriptase
Study NCT02543164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: REFERENCE: white bread
Description: Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).
Study NCT02543164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TEST: b-glucan enriched bread
Description: Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).
Study NCT00099320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
Study NCT00099320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
Study NCT01136005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dexpanthenol 5% cream
Description: Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
Study NCT01136005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetomacrogol cream
Description: Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
Study NCT03998215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria booster vaccination
Description: Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
Study NCT03943121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steroid-eluting stent implant
Description: After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
Study NCT03943121 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Without Steroid-eluting stent implant
Description: After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
Study NCT04440163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis groups A, B, C, W, and Y vaccine
Study NCT04440163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo
Study NCT04440163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba
Description: Bivalent recombinant lipoprotein 2086 vaccine
Study NCT04440163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine
Study NCT03339531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2D radiotherapy
Study NCT04307225 — intervention group
Intervention type: DEVICE
Intervention: Zenicor
Description: Handheld Thumb ECG monitoring device
Study NCT05000918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Okara protein hydrolysate (OPH)
Description: Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
Study NCT01213758 — intervention group
Intervention type: OTHER
Intervention: Measuring liver function by PET/CT
Description: Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors